Megan Cheah Xin Yan
Research Subjects
Megan Cheah Xin Yan has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Bingsen Zhang
Boyce Thompson Institute, Cornell University, Ithaca, USA
1 shared publication - Edward T. Chouchani
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA
1 shared publication - Evanna L. Mills
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, USA
1 shared publication Guangyan Du
Department of Chemical and Systems Biology, CHEM-H and SCI, Stanford Medical School, Stanford University, Stanford, USA
1 shared publication- Haopeng Xiao
Department of Biochemistry, Stanford University, Stanford, USA
1 shared publication Haruna Takeda
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
1 shared publication
Latest Publications
- 15 September 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (10) , 2048-2050
The high price of ‘free’ cysteine
- 15 September 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (10) , 2048-2050
The high price of ‘free’ cysteine
- Open Access
- 12 March 2026
- Published by Springer Nature in Nature Chemical Biology
- Vol. 22 (7) , 1187-1200
A druggable redox switch on SHP1 controls macrophage inflammation
Immunological proteins are major disease targets, yet most remain undrugged. Post-translational redox modification of cysteine residues has emerged as an important mode of immune cell regulation, particularly in macrophage cytokine responses. Here we develop a strategy for systematic discovery and small-molecule functionalization of redox-regulated cysteines on immunological proteins. Using deep redox proteomics, we annotate 788 in vivo redox-regulated cysteines across diverse immune-relevant protein domains. We demonstrate how these sites enable cysteine-directed pharmacology through discovery of a novel cysteine activation site on the immune regulator SHP1. Targeting C102, we develop a highly selective covalent agonist, SCA, which binds the N-SH2 domain to relieve autoinhibition and activate SHP1. In mouse and human macrophages, SCA selectively engages SHP1 C102, antagonizing interleukin-1 receptor-associated kinase signaling and lipopolysaccharide-induced proinflammatory cytokine production. Together, this work identifies a druggable cysteine redox switch controlling macrophage cytokine responses and provides a compendium of redox-regulated sites for therapeutic development.
- 12 March 2026
- Published by Springer Nature in Nature Chemical Biology
- Vol. 22 (7) , 1187-1200
Open AccessA druggable redox switch on SHP1 controls macrophage inflammation
Immunological proteins are major disease targets, yet most remain undrugged. Post-translational redox modification of cysteine residues has emerged as an important mode of immune cell regulation, particularly in macrophage cytokine responses. Here we develop a strategy for systematic discovery and small-molecule functionalization of redox-regulated cysteines on immunological proteins. Using deep redox proteomics, we annotate 788 in vivo redox-regulated cysteines across diverse immune-relevant protein domains. We demonstrate how these sites enable cysteine-directed pharmacology through discovery of a novel cysteine activation site on the immune regulator SHP1. Targeting C102, we develop a highly selective covalent agonist, SCA, which binds the N-SH2 domain to relieve autoinhibition and activate SHP1. In mouse and human macrophages, SCA selectively engages SHP1 C102, antagonizing interleukin-1 receptor-associated kinase signaling and lipopolysaccharide-induced proinflammatory cytokine production. Together, this work identifies a druggable cysteine redox switch controlling macrophage cytokine responses and provides a compendium of redox-regulated sites for therapeutic development.